Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
More Stories
Stock-market indicator with a near-perfect track record is flashing a ‘buy’ signal
One closely-watched stock-market indicator is flashing a bright-red buy signal as more companies’ shares join the rally.
Investors see risks that the inflation battle isn’t over yet
Concerns that inflation might not be so easily defeated are starting to creep back into financial markets
China stock-market jump may be ‘tradable rally’ — but approach with caution
Chinese stocks and the exchange-traded funds that track them surged Tuesday after Beijing announced the biggest stimulus package since the...
How Caroline Ellison almost avoided prison in the criminal collapse of FTX
Prosecutors say Ellison proved essential in unraveling the theft of $8 billion in customer deposits and sending Sam Bankman-Fried to...
KB Home saw better demand for its homes as mortgage rates dropped
That message of optimism was not resonating with investors late Tuesday.
Stitch Fix forecast sinks stock, as CEO says ‘there is a lot of work’ for turnaround
Shares of Stitch Fix Inc. fell after hours on Tuesday after the online styling service forecast quarterly and full-year sales...